Mismatch Amplification Mutation Assay (MAMA)-Based Real-Time PCR for Rapid Detection of  and Antimicrobial Resistance Determinants in Clinical Specimens. by Donà, Valentina et al.
Mismatch Ampliﬁcation Mutation Assay-Based Real-Time
PCR for Rapid Detection of Neisseria gonorrhoeae and
Antimicrobial Resistance Determinants in Clinical Specimens
Valentina Donà,a* Joost H. Smid,b Sara Kasraian,a Dianne Egli-Gany,b Ferah Dost,c Fatime Imeri,d Magnus Unemo,e
Nicola Low,b Andrea Endimiania
aInstitute for Infectious Diseases, University of Bern, Bern, Switzerland
bInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
cAmbulatorium Kanonengasse, Zurich, Switzerland
dLaborgemeinschaft 1, Zurich, Switzerland
eWHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden
ABSTRACT Molecular methods are often used for Neisseria gonorrhoeae detection,
but complete deﬁnition of antimicrobial resistance (AMR) patterns still requires phe-
notypic tests. We developed an assay that both identiﬁes N. gonorrhoeae and de-
tects AMR determinants in clinical specimens. We designed a mismatch ampliﬁcation
mutation assay (MAMA)-based SYBR green real-time PCR targeting one N. gonorrhoeae-
speciﬁc region (opa); mosaic penA alleles (Asp345 deletion [Asp345del], Gly545Ser) as-
sociated with decreased susceptibility to cephalosporins; and alterations conferring
resistance to ciproﬂoxacin (GyrA Ser91Phe), azithromycin (23S rRNA A2059G and
C2611T), and spectinomycin (16S rRNA C1192T). We applied the real-time PCR to
489 clinical specimens, of which 94 had paired culture isolates, and evaluated its
performance by comparison with the performance of commercial diagnostic molecu-
lar and phenotypic tests. Our assay exhibited a sensitivity/speciﬁcity of 93%/100%,
96%/85%, 90%/91%, 100%/100%, and 100%/90% for the detection of N. gonorrhoeae
directly from urethral, rectal, pharyngeal, cervical, and vaginal samples, respectively.
The MAMA strategy allowed the detection of AMR mutations by comparing cycle
threshold values with the results of the reference opa reaction. The method accu-
rately predicted the phenotype of resistance to four antibiotic classes, as determined
by comparison with the MIC values obtained from 94 paired cultures (sensitivity/
speciﬁcity for cephalosporins, azithromycin, ciproﬂoxacin, and spectinomycin resistance,
100%/95%, 100%/100%, 100%/100%, and not applicable [NA]/100%, respectively, in gen-
ital specimens and NA/72%, NA/98%, 100%/97%, and NA/96%, respectively, in extrageni-
tal specimens). False-positive results, particularly for the penA Asp345del reaction, were
observed predominantly in pharyngeal specimens. Our real-time PCR assay is a
promising rapid method to identify N. gonorrhoeae and predict AMR directly in geni-
tal specimens, but further optimization for extragenital specimens is needed.
KEYWORDS gonococcus, antimicrobial resistance, NAAT, real-time PCR, clinical
samples, AMR, Neisseria gonorrhoeae, antibiotic resistance, clinical methods,
diagnostics, rapid tests, sexually transmitted diseases
Neisseria gonorrhoeae is the causative agent of the sexually transmitted infectiongonorrhea. More than 90% of the estimated 78 million new cases of gonorrhea
each year occur in low- and middle-income countries, where access to diagnosis and
treatment is often limited (1). Despite international efforts to promote preventive
strategies and ensure adequate treatment, N. gonorrhoeaemay develop mechanisms of
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resistance to all antimicrobials that have been recommended for empirical ﬁrst-line
treatment (2–4).
Commercial nucleic acid ampliﬁcation tests (NAATs) have replaced culture-based
methods for the diagnosis of gonococcal infections in many settings. However, a
recognized disadvantage of these assays is that they do not provide any information
about antimicrobial resistance (AMR) patterns (5). Culture methods are time-consuming
and limited by stringent sampling, transport, and culture conditions, but they remain
essential for surveillance to identify changes in AMR trends, detect emerging resistance
patterns, and inform prompt revision of treatment guidelines (6, 7). The importance of
developing NAATs that detect and predict AMR determinants has been clearly recog-
nized, both to enhance culture-based AMR surveillance and, potentially, to support
clinicians to provide individualized therapies (5, 8–10).
Most key molecular mechanisms that confer resistance to currently and previously
recommended antimicrobials for gonorrhea are known. The presence of mosaic penA
alleles encoding penicillin binding protein 2 (PBP2) has been associated with decreased
susceptibility and resistance to extended-spectrum cephalosporins (ESCs). For instance,
the mosaic penA XXXIV allele, present in the successful internationally spreading clone
with N. gonorrhoeae multiantigen sequence typing (NG-MAST) sequence type 1407
(ST1407), as well as in other strains belonging to the same genogroup (11–14), has
resulted in clinical treatment failures with ESCs worldwide (15). A Ser91Phe substitution
in GyrA is present in all documented ciproﬂoxacin (CIP)-resistant gonococcal strains
(16). Moderate- and high-level resistance to azithromycin (AZM) is associated with the
single nucleotide polymorphism (SNP) C2611T or A2059G in at least three of the four
23S rRNA alleles (17, 18). The SNP C1192T in the 16S rRNA gene confers spectinomycin
(SPC) resistance (19).
Many PCR-based tests to detect molecular determinants predicting resistance to
a single antibiotic have been developed, but there have been only a few published
attempts to develop assays that predict AMR to multiple drugs (20). We previously
developed a multiplex high-resolution melting (HRM)-based real-time PCR to detect N.
gonorrhoeae and seven genetic AMR determinants in clinical isolates (21). However,
cross-ampliﬁcation of Neisseria spp. and the relatively high limit of detection (LOD)
suggested that our assay would not be suitable for direct testing of clinical specimens.
To overcome the limitations of our previously presented assay (20), we developed
a new rapid SYBR green-based real-time PCR method based on a mismatch ampliﬁca-
tion mutation assay (MAMA) strategy (22). This approach relies on strategic primer
design to selectively amplify a target sequence only in the presence of the AMR
mutation of interest while suppressing wild-type ampliﬁcation. The objectives of this
study were to describe our new MAMA-based SYBR green real-time PCR and report on
its performance for the identiﬁcation (ID) of N. gonorrhoeae and detection of gonococ-
cal AMR determinants directly in clinical specimens.
MATERIALS AND METHODS
Design of the real-time PCR assay. Eight primer sets were designed with Oligo Primer Analysis
software (v4.0; Molecular Biology Insights) to amplify speciﬁc sequences of the targets described in Table
1. For ID, primers that amplify the gonococcal upstream regions of opa and porA were designed (21).
For the AMR determinants, one primer was designed to match at its 3= end the mutations of interest
in the penA, gyrA, 23S rRNA, and 16S rRNA genes, and a mismatch in the second to the last base pair at
the 3= end was added. This strategy was also applied to the lower primer of the 16S rRNA reaction to
improve discrimination from other Neisseria spp. For both mosaic penA reactions (reactions for the penA
Asp345 deletion [Asp345del] and penA Gly545Ser), the primer design also took advantage of mosaic/
allele-speciﬁc regions in penA.
Neisseria control strains for method validation. Extraction of genomic DNA (gDNA) from culture
strains for validation of the real-time PCR method was performed using a QIAamp DNA minikit (Qiagen).
Each 20-l reaction mixture contained 0.2 M each primer, 1 MeltDoctor master mix (Applied
Biosystems) containing the SYBR green derivative Syto, and 20 ng (or deﬁned copy numbers) of gDNA.
Each sample was tested in duplicate. Experiments were run on a QuantStudio 7 Flex instrument (Applied
Biosystems). The PCR program parameters included an initial denaturation step (95°C, 10 min), followed
by 40 cycles of denaturation (95°C, 15 s), annealing (62°C, 10 s), and extension (72°C, 10 s). Results were
analyzed with QuantStudio 6 and 7 Flex real-time PCR software (v1.0; Applied Biosystems). To assess the
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LOD of the method, known quantities of gDNA copy numbers per reaction mixture were tested in 10-fold
serial dilutions.
We tested a panel of 45 N. gonorrhoeae strains that included 26 previously fully characterized strains
with known proﬁles of MICs and genetic AMR determinants (23); GC3 (with the 16S rRNA C1192T
mutation; SPC MIC,1,024 g/ml); GC4 (harboring four 23S rRNA alleles with the A2059G mutation; AZM
MIC, 256 g/ml); G07 (harboring four 23S rRNA alleles with the C2611T mutation; AZM MIC, 8 g/ml)
(21); the fully susceptible reference strain ATCC 49226; and WHO reference strains (24) WHO A; WHO F;
WHO G; WHO L; WHO K and WHO W (WHO K and WHO W carry a mosaic penA X allele; MIC of ceﬁxime
[CFM], 0.25 and 0.5 g/ml, respectively); WHO M; WHO N; WHO O (with the 16S rRNA C1192T mutation;
SPC MIC, 1,024 g/ml); WHO P; WHO U (harboring four 23S rRNA alleles with the C2611T mutation;
AZM MIC, 4 g/ml); WHO V (harboring four 23S rRNA alleles with the A2059G mutation; AZM MIC, 256
g/ml), WHO Y (carrying a mosaic penA XXXIV with an additional Ala501Pro alteration; MICs for CFM and
ceftriaxone [CRO], 2 and 1.5 g/ml, respectively); and WHO X and WHO Z (both of which carry a mosaic
penA allele; MICs for CFM and CRO, 4 and 2 g/ml, respectively, for WHO X and 2 and 0.5 g/ml,
respectively, for WHO Z) (24, 25). All N. gonorrhoeae isolates were grown on chocolate agar PolyVitex
plates (bioMérieux) for 24 h at 35°C in a humid 5% CO2-enriched atmosphere.
Twenty clinical nongonococcal Neisseria strains previously identiﬁed by matrix-assisted laser desorp-
tion ionization–time of ﬂight mass spectrometry (MALDI-TOF MS; Bruker Daltonics) were also tested to
assess cross-reactivity. The panel included N. meningitidis (n  3), N. sicca (n  3), N. ﬂavescens (n  3),
N. mucosa (n  2), N. cinerea (n  2), N. subﬂava (n  2), N. lactamica (n  1), N. ﬂava (n  1), N. weaveri
(n  1), N. polysaccharea (n  1), and N. bacilliformis (n  1) strains.
N. gonorrhoeae-positive and N. gonorrhoeae-negative clinical specimens. From May 2015 to
June 2016, we collected 819 clinical specimens, using ESwabs (Copan Diagnostics Inc.), from 261 patients
at three study centers in Switzerland (Checkpoint Zurich, Zurich, Switzerland; Ambulatorium Kanonen-
gasse, Zurich, Switzerland; Department of Infectious Diseases, Bern University Hospital, Bern, Switzer-
land). Our study population consisted of 240 (92.0%) men, of which 230 (88.1%) were men who have sex
with men (MSM), and 21 (8.0%) women. This study was conducted according to the Declaration of
Helsinki and was approved by the ethics committees in Bern and Zurich (EK BE 244/14 and EK ZH
2014-0587, respectively).
These samples were tested for N. gonorrhoeae by culture and by the Aptima Combo 2 assay (Hologic
Inc.) (n 238 patients) at the laboratory Laborgemeinschaft 1 (Zurich, Switzerland) or by the Cobas CT/N.
gonorrhoeae assay (Roche Molecular Diagnostics) (n  23 patients) at the Clinical Microbiology Labora-
tory of the Institute for Infectious Diseases, University of Bern, Bern, Switzerland (see Table S1 in the
supplemental material). After routine testing and storage at 80°C, residual ESwabs and cultures were
transported periodically (i.e., approximately every 2 months for samples from the laboratory of Laborge-
meinschaft 1) to the Institute for Infectious Diseases (University of Bern, Bern, Switzerland) and stored at
80°C before implementation of the new MAMA-based SYBR green real-time PCR.
A QIAamp DNA minikit (Qiagen) was used to extract total DNA from 200 l of the residual ESwab
specimens which met the minimum requirements for further testing with our method. Reasons for
exclusion included the following: 200 l sample was left, transport/delivery was delayed, the samples
TABLE 1 Primers implemented for the real-time PCR assay, target mutations, and the corresponding affected antibioticsa
Target Primer name Primer sequenceb Associated target (purpose or antibiotic affected)
opa opa_F 5=-GTTCATCCGCCATATTGTGTTGA-3= opa (Neisseria gonorrhoeae identiﬁcation)
opa_R 5=-AAGGGCGGATTATATCGGGTTCC-3=
porA porA_F 5=-CTATGCCCATGGTTTCGACTTTG-3= porA (N. gonorrhoeae identiﬁcation, conﬁrmatory)
porA_R 5=-CATAGCTGGTATGTTCGCGTTTC-3=
penA Gly545Ser 545_F 5=-TGGTTAACGGTCGTTACGTCGATT-3= Mosaic penA (decreased susceptibility/resistance to ESCs)
545_R 5=-GGCCCTGCCACTACACCGTT-3=
penA Asp345del 345_F 5=-GGCAAAGTGGATGCAACCGAT-3= Mosaic penA (decreased susceptibility/resistance to ESCs)
345_R 5=-GATAAACGTGGGTATCTTGTACGG-3=
23S rRNA C2611T C2611_F 5=-AACGTCGTGAGACAGTTTGGTTT-3= 23S rRNA C2611T (moderate AZM resistance)
C2611_R 5=-GAACTTAGCTACCCGGCTATGCA-3=
23S rRNA A2059G A2059_F 5=-TACAGTAAAGGTTCACGGGGTCAC-3= 23S rRNA A2059G (high AZM resistance)
A2059_R 5=-ATGGCCACACTGTCTCCTCCC-3=
gyrA Ser91Phe gyrA_S91_F 5=-AATACCACCCCCACGGCGATCT-3= GyrA Ser91Phe (CIP resistance)
gyrA_S91_R 5=-TCTATCAGCACATAACGCATAGCG-3=
16S rRNA C1192T 16S_1192_F 5=-CTTGTCATTAGTTGCCATCATTTG-3= 16S rRNA C1192T (SPC resistance)
16S_1192_R 5=-TAAGGGCCATGAGGACTTGATA-3=
aESCs, extended-spectrum cephalosporins; AZM, azithromycin; CIP, ciproﬂoxacin; SPC, spectinomycin.
bAll nontemplate base pairs compared to the wild-type sequence are underlined.
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could not be tested immediately after DNA extraction, and/or the extragenital samples could not be
tested immediately after arrival. For each PCR, 4 l of extracted total DNA was used, and the real-time
PCR was performed as described above.
Establishment of cycle threshold (CT) ranges for the detection of AMR determinants. Detection
of mutations in the target genes was based on the difference in the cycle threshold (ΔCT) values between
the reference opa reaction and each AMR determinant reaction. We used the N. gonorrhoeae control
isolates (tested in duplicate) to determine the optimal ΔCT for the detection of each AMR determinant
using the Youden index, which maximized the sum of sensitivity and speciﬁcity (26). We then rounded
the value to the nearest whole number and added 1 to account for intersample variability. Adding 1
minimized the number of false-negative results when applied to the clinical samples, which tended to
have ΔCT values higher than the ones observed for culture isolates (data not shown).
Establishment of the CT cutoff point for the detection of N. gonorrhoeae in clinical specimens.
We used the results of the commercial NAATs as the reference standard and determined the cutoff point
for the opa CT value to classify positive and negative results. In particular, we examined the distributions
of CT values for specimens with positive and negative reference test results and determined the optimal
cutoff point that maximized the sum of the sensitivity and the speciﬁcity for the detection of N.
gonorrhoeae (26).
Analysis of the real-time PCR results in clinical specimens. For N. gonorrhoeae identiﬁcation,
results from the opa reaction were interpreted as positive if the CT value was below the cutoff point. We
calculated the sensitivity and the speciﬁcity with 95% conﬁdence intervals (CI; determined using the
Clopper-Pearson method) by comparison with the results of commercial NAAT testing as the reference
standard (27).
For the detection of AMR determinants, the results were interpreted as follows: (i) a positive penA
Asp345del reaction (indicating the presence of a mosaic penA allele) without or with a positive penA
Gly545Ser reaction (indicating the presence of a penA mosaic XXXIV) for strains with decreased suscep-
tibility to CFM and/or CRO; (ii) the presence of the 23S rRNA C2611T or A2059G mutation for strains
moderately or highly resistant to AZM, respectively; (iii) the presence of gyrA with the Ser91Phe
substitution for strains nonsusceptible to CIP; and (iv) the presence of the 16S rRNA C1192T mutation for
strains resistant to SPC.
We calculated the sensitivity and the speciﬁcity with the 95% CI of the real-time PCR AMR reactions
using as the reference standard either their molecular characterization or the antimicrobial susceptibility
based on the MICs for CRO, CFM, AZM, CIP, and SPC of culture isolates. MICs were obtained with the Etest
(bioMérieux) method on chocolate agar PolyVitex plates (bioMérieux) and categorized using the 2016
European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria for all antimicrobials
except AZM, for which a breakpoint of an MIC of2 g/ml was used, as described previously (21, 28–30).
RESULTS AND DISCUSSION
Method design and validation using control strains. To detect SNPs in the 23S
rRNA, gyrA, and 16S rRNA genes associated with resistance to AZM, CIP, and SPC,
respectively (16–19), we used the MAMA method to design primers to selectively
amplify mutated alleles while suppressing wild-type ampliﬁcation (Table 1) (22). Brieﬂy,
the sequence of one primer matched at the 3= end the mutation of interest, and a
nontemplate base was introduced in the second to the last base at the 3= end. Based
on previous observations (22), this was expected not to inﬂuence the ampliﬁcation of
a mutated allele while strongly inhibiting wild-type ampliﬁcation.
To assess the presence or absence of a particular AMR determinant, particularly
when testing clinical specimens with an unknown gonococcal DNA concentration, we
established the opa reaction for species ID as the reference reaction to determine the
presence of an AMR mutation of interest. We expected that, in the presence of the
target mutation, the CT values of the reference reaction (opa) and of the AMR deter-
minant reaction would be similar, whereas the CT in the presence of a wild-type
sequence would be substantially delayed. When testing the panel of 45 fully charac-
terized gonococcal isolates, the CT values of the AMR reactions in the presence of the
target determinants were close to the CT values of the opa reference reaction (Table 2).
Conversely, in the presence of a wild-type sequence, we observed a delay of at least 8
additional CTs in all four AMR reactions (see Table S2 and examples in Fig. S1 in the
supplemental material).
At the time of primer design, mosaic penA patterns X and XXXIV were the most
frequently identiﬁed mosaic alleles. Therefore, we designed a reaction (penA Asp345del)
targeting both these alleles, i.e., the penA mosaic region, including an Asp345 deletion in
PBP2 compared to the sequence of nonmosaic penA alleles (31), and a reaction (penA
Gly545Ser) speciﬁcally targeting the penA region of the Gly545Ser substitution of the
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penA mosaic XXXIV allele (32) in order to discriminate mosaic penA XXXIV from mosaic
penA X alleles.
Consistently, when testing the penA Asp345del reaction, ampliﬁcation in the pres-
ence of a mosaic penA X or XXXIV allele occurred with a ΔCT value of 2.6 compared
to the reference opa reaction, while for nonmosaic penA alleles, we observed a ΔCT of
16.9. For the penA Gly545Ser reaction, ampliﬁcation in the presence of the mosaic
penA XXXIV allele occurred with a ΔCT of 3.2 compared to the opa reaction; in
contrast, for the mosaic penA X allele, a signiﬁcant delay in ampliﬁcation was observed
(ΔCT  19.3). However, both reactions were considered negative for mosaic penA-
harboring strains WHO X and WHO Z (CT, 40 for the penA Gly545Ser reaction; ΔCT,
9.7 for the penA Asp345del reaction; Table S2), indicating that such rare H041-like
mosaic penA alleles cannot be identiﬁed. Nevertheless, isolates harboring these alleles
have remained rare (33–35). A posterior in silico analysis of the 22 mosaic penA alleles
available in the NG-STAR database (36) in February 2018 also revealed that mosaic penA
patterns XXXV, 37, 38, 59, 60, 62, 63, and 74 might not be detected with the penA
Asp345del reaction (data not shown). For the penA Gly545Ser reaction, we would
expect that, in addition to a mosaic penA XXXIV pattern, mosaic penA patterns 42, 51,
52, 55, and 67 would also yield a positive result, owing to the 100% sequence homology
in the primer sequences.
Using the Youden index, we determined the maximum ΔCT within which the AMR
reaction was considered positive (Table 2); samples with a higher ΔCT were considered
not to possess the AMR determinant (examples are shown in Fig. S2). The analytical
LOD for all reactions was 10 to 100 gDNA copies/reaction in the presence of the
mutation of interest, whereas wild-type ampliﬁcation within 40 cycles was observed
only when testing 105 gDNA copies (23S rRNA C2611T and A2059G, gyrA S91F) and
107 gDNA copies (16S rRNA 1192T).
Using these cutoffs, our method showed 100% sensitivity and speciﬁcity for the
prediction of phenotypic resistance to AZM and CIP in the 45 gonococcal control strains
in less than 1 h (and in less than 2 h when the DNA extraction time is included) (Table
S3). It should be noted that our method detects only the presence of the AZM-
associated resistance mutations and not the number of mutated alleles, so we might
detect AZM-susceptible gonococci with only 1 or 2 mutated alleles. However, since
these strains are at risk of quickly mutating more alleles, especially if exposed to AZM
selective pressure (18), it is still relevant to detect such strains and treat them as
potentially AZM resistant.
Prediction of ESC resistance was less accurate (sensitivity, 62%; speciﬁcity, 86%) for
three main reasons: (i) the H041-like penA alleles harbored in strains WHO X and WHO
Z were not detected, (ii) the ESC-resistant strain WHO L possessed a nonmosaic penA
allele, and (iii) the presence of a mosaic penA allele is often associated with raised MICs
for ESCs which are still in the susceptible range on the basis of EUCAST criteria (21, 37).
Our assay also did not predict SPC resistance in strain WHO A, which has a resistance
TABLE 2 Establishment of the ΔCTa for each AMR reaction based on the results for the
Neisseria gonorrhoeae control isolates
Target
No. of
wild-type
strains
CT range for
wild-type
strainsb
No. of
mutant
strains
CT range for
mutant strains
Established
CT for
positivity
penA Gly545Ser 37 15.65 to 25.8 8 0.21 to 3.17 4
penA Asp345del 35c 9.65 to 25.25 10 0.86 to 2.64 4
23S rRNA C2611T 43 7.60 to 12.84 2 0.12 to 1.82 1
23S rRNA A2059G 43 9.35 to 15.20 2 0.73 to 0.76 2
gyrA Ser91Phe 15 13.92 to 16.93 30 1.01 to 5.78 7
16S rRNA C1192T 43 17.07 to 24.12 2 6.67 to 9.35 10
aΔCT, difference between the CT of the AMR reaction and the CT of the opa reaction.
bWhen the CT was 40, the upper range could not be estimated precisely.
cResults for strains WHO X and WHO Z, carrying a rare mosaic penA allele, were considered negative and
included in the range for wild-type isolates.
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mutation in rpsE. This single amino acid alteration confers low-level SPC resistance and
has been only rarely described (38). The assay successfully detected the more common
16S rRNA C1192T mutation, which is associated with high-level SPC resistance, in strains
WHO O and GC3.
Cross-reaction with nongonococcal Neisseria spp. Cross-reactivity with the N.
meningitidis and commensal Neisseria spp. naturally found in the pharyngeal ﬂora poses
a great challenge in the development of molecular diagnostic tests for detecting AMR
determinants in N. gonorrhoeae (20, 39). We expected that, even in the presence of
100% homology with the wild-type allele in a gonococcal species, the MAMA method
would strongly inhibit background ampliﬁcation from commensal sequences.
The MAMA strategy was also applied to the lower primer of the 16S rRNA reaction
to improve discrimination from nongonococcal species, as described previously (39).
Little or no cross-ampliﬁcation was observed for the penA Gly545Ser and 16S rRNA
C1192T reactions, when 107 gDNA copies/reaction of 20 strains from different cultured
Neisseria spp. were tested (Table S4). Nevertheless, cross-reactivity at a high CT (mostly
comparable to those for N. gonorrhoeae wild-type sequences) was observed for the
penA Asp345del reaction and both 23S rRNA reactions. This was due to the high
similarity of the target sequences among different Neisseria spp.; notably, mosaic penA
alleles most likely arose through recombination with the commensal orthologs (40, 41).
Testing of N. gonorrhoeae-positive and N. gonorrhoeae-negative clinical spec-
imens. During our study, we collected a total of 891 ESwab samples from 261 patients,
with 159 paired culture isolates being available from 128 patients. Of the 891 ESwab
samples, 489 (54.9%), including 94 with paired culture isolates, met the requirements
for further testing with our method (Tables S1 and S5). The 489 samples included
urethral (n 177), pharyngeal (n 158), rectal (n 130), vaginal (n 13), and cervical
(n  11) specimens (Table S1), of which 160 were N. gonorrhoeae positive (pharyngeal,
n  59; rectal, n  48; urethral, n  46; cervical, n  4; vaginal, n  3) and 329 were
N. gonorrhoeae negative (urethral, n  131; rectal, n  82; pharyngeal, n  99; cervical,
n  7; vaginal, n  10) by previous commercial NAAT testing.
When testing the NAAT-negative samples, nonspeciﬁc ampliﬁcation of the opa
reaction was observed in most samples of all specimen types (i.e., the proportions of
samples with an opa CT of40 were 11.1%, 18.3%, 18.3%, 25%, and 0% for pharyngeal,
urethral, rectal, vaginal, and cervical specimens, respectively), possibly due to sample
degradation, suboptimal primer speciﬁcities/PCR conditions, and/or background am-
pliﬁcation from commensals. The potential of background ampliﬁcation for opa was
also conﬁrmed when testing the panel of nongonococcal control strains at 107 gDNA
copies/reaction (i.e., cross-reactivity was observed for N. meningitidis, N. mucosa, and N.
weaveri; Table S4). For these reasons, we analyzed the distributions of the opa CT values
for specimens with positive and negative commercial NAAT results in order to deter-
mine the optimal cutoff point (i.e., the maximum CT value for which the sample would
be considered positive for the presence of N. gonorrhoeae). We initially evaluated the
addition of the porA reaction as a conﬁrmatory identiﬁcation reaction. However, we
eventually dismissed it since this reaction did not perform well and led to inconsistent
results with the opa reaction (data not shown).
Overall, using the optimal cutoffs for opa (e.g., a CT of 26.1 for urethral samples;
Table 3), our method showed good agreement with the reference NAATs for the
detection of N. gonorrhoeae in genital specimens (e.g., a sensitivity of 93% and a
speciﬁcity of 100% for urethral samples), but additional testing on different sample sets
will be required in the future to conﬁrm the accuracy of the established cutoffs. The
real-time PCR was less accurate in identifying N. gonorrhoeae in extragenital specimens.
In particular, the low speciﬁcity resulting in a low positive predictive value indicates that
further optimization of the method is needed to increase the accuracy for these sample
types (Table 3).
All 94 samples from 77 patients for which paired culture isolates were available
tested positive for N. gonorrhoeae by using our real-time PCR (Tables S1 and S5).
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Additionally, our method accurately predicted (directly from the clinical ESwab sam-
ples) the susceptibility proﬁles for CIP, AZM, SPC, and ESCs of the paired culture isolates,
as determined by comparison with the MICs as the gold standard (Table 4).
Our assay predicted CIP resistance with a 100% sensitivity and a 98% speciﬁcity. One
clinical sample that tested positive by the mosaic penA reaction (penA Asp345del) had
a paired isolate that carried a mosaic penA X allele and was phenotypically resistant to
CFM (28). This isolate was subjected to PCR/sequencing (23), conﬁrming the presence
of a mosaic penA X allele. Similarly, all three samples that tested positive for both penA
Asp345del and penA Gly545Ser had paired isolates that contained the mosaic penA
XXXIV allele, despite being phenotypically susceptible to ESCs according to the EUCAST
criteria. This is not surprising, since strains harboring this particular allele often show
only raised ESC MICs which are still in the susceptible range (37). Nevertheless, the
detection of such strains is still of clinical relevance, since isolates harboring this mosaic
penA variant (e.g., the internationally spreading clone NG-MAST ST1407) have been
associated with CFM treatment failures, despite being susceptible on the basis of
standard phenotypic testing (42). Overall, our assay showed a 100% sensitivity and a
98% to 100% speciﬁcity for the prediction of the AMR phenotype for all reactions
except the penA Asp345del reaction (82% speciﬁcity). False-positive results were mainly
associated with the penA Asp345del reaction in extragenital specimens (i.e., likely due
to the background ampliﬁcation of other Neisseria spp.). In fact, the speciﬁcities of the
TABLE 3 Optimal opa CT cutoff value and performance of the real-time PCR for Neisseria
gonorrhoeae identiﬁcation compared to that of commercial NAATsa
Sample site
opa
cutoff
No. of isolates with the
following result:
Sensitivity
(95% CI)b
Speciﬁcity
(95% CI)bTP FP FN TN Total
Urethra 26.1 43 0 3 131 177 0.93 (0.82, 0.99) 1.00 (0.97, 1.00)
Rectum 33.7 46 12 2 70 130 0.96 (0.86, 0.99) 0.85 (0.76, 0.92)
Pharynx 31.3 53 9 6 90 158 0.90 (0.79, 0.96) 0.91 (0.83, 0.96)
Cervix 28.4 4 0 0 7 11 1.00 (0.4, 1.00) 1.00 (0.59, 1.00)
Vagina 33.4 3 1 0 9 13 1.00 (0.29, 1.00) 0.90 (0.55, 1.00)
All sites combined 33 149 22 11 307 489 0.92 (0.87, 0.96) 0.91 (0.87, 0.94)
aCI, conﬁdence interval; TP, true positive; FP, false positive; FN, false negative; TN, true negative.
bSensitivity and speciﬁcity were calculated using the results of the commercial NAATs as the reference
standard.
TABLE 4 Performance of the real-time PCR in predicting antimicrobial resistance to four
antibiotic classes directly from Neisseria gonorrhoeae-positive clinical specimens with
paired N. gonorrhoeae isolatesa
Reaction
Associated
antibiotic
No. of isolates with
the following result:
Sensitivity
(95% CI)b
Speciﬁcity
(95% CI)bTP FP FN TN Total
penA Asp345del  penA
Gly545Ser
ESCs 1c 17d 0 76 94 1.00 (0.03, 1.00) 0.82 (0.72, 0.89)
23S rRNA C2611T and/or
23S rRNA A2059G
AZM 1 1 0 92 94 1.00 (0.03, 1.00) 0.99 (0.94, 1.00)
gyrA Ser91Phe CIP 41 1 0 52 94 1.00 (0.91, 1.00) 0.98 (0.90, 1.00)
16S rRNA C1192T SPC 0 2 0 92 94 NA 0.98 (0.93, 1.00)
aCI, conﬁdence interval; TP, true positive; FP, false positive; FN, false negative; TN, true negative; ESCs,
extended-spectrum cephalosporins; AZM, azithromycin; CIP, ciproﬂoxacin; SPC, spectinomycin; NA, not
applicable.
bSensitivity and speciﬁcity were calculated on the basis of the susceptibility phenotype (MICs) of the paired
culture isolates.
cThis isolate harbored a penA mosaic X allele and was correctly identiﬁed as ESC resistant by the penA
Ala345del reaction.
dThree isolates were correctly predicted to harbor a mosaic penA allele on the basis of the molecular
characterization but were susceptible to ESCs.
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penA Asp345del reaction observed for genital and extragenital specimens were 95%
and 72%, respectively (Tables 5 and 6).
A main limitation of the present study was that we did not identify clinical samples
positive for some AMR mutations (i.e., 23S rRNA A2059G and 16S rRNA C1192T), since
they are still very rare (15), and only a few positive results for additional AMR deter-
minants (i.e., 23S rRNA C2611T and mosaic penA alleles) were recorded. In this context,
the results obtained from the remaining 55 samples, for which no culture isolates were
available, also suggest that the number of samples testing positive for ESC, AZM, and
SPC resistance overestimates the presence of these resistance determinants in extra-
genital specimens (Table S6). This ﬁnding likely results from false-positive results due to
cross-reactivity with other Neisseria spp. (Tables S4). Additionally, lower gonococcal
loads in extragenital specimens, also typically associated with the inability to recover
culture isolates, may also lead to a higher opa CT and, thus, a decreased ΔCT (Fig. S3;
Table S7). Finally, samples were processed at different times after collection and could
not be tested fresh, potentially allowing degradation.
Overall, further evaluations will be beneﬁcial to conﬁrm the performance of our
method with genital specimens, and in particular, more sample sets with different AMR
TABLE 5 Performance of the real-time PCR in predicting antimicrobial resistance to four
antibiotic classes directly from Neisseria gonorrhoeae-positive genital specimens with
paired N. gonorrhoeae isolatesa
Reaction
Associated
antibiotic
No. of isolates with
the following result:
Sensitivity
(95% CI)b
Speciﬁcity
(95% CI)bTP FP FN TN Total
penA Asp345del  penA
Gly545Ser
ESCs 1c 2d 0 37 40 1.00 (0.03, 1.00) 0.95 (0.83, 0.99)
23S rRNA C2611T and/or
23S rRNA A2059G
AZM 1 0 0 39 40 1.00 (0.03, 1.00) 1.00 (0.91, 1.00)
gyrA Ser91Phe CIP 18 0 0 22 40 1.00 (0.81, 1.00) 1.00 (0.85, 1.00)
16S rRNA C1192T SPC 0 0 0 40 40 NA 1.00 (0.91, 1.00)
aCI, conﬁdence interval; TP, true positive; FP, false positive; FN, false negative; TN, true negative; ESCs,
extended-spectrum cephalosporins; AZM, azithromycin; CIP, ciproﬂoxacin; SPC, spectinomycin; NA, not
applicable.
bSensitivity and speciﬁcity were calculated on the basis of the susceptibility phenotype (MICs) of the paired
culture isolates.
cThis isolate harbored a penA mosaic X allele and was correctly identiﬁed as ESC resistant by the penA
Asp345del reaction.
dOne isolate was correctly predicted to harbor a mosaic penA allele on the basis of the molecular
characterization but was susceptible to ESCs.
TABLE 6 Performance of the real-time PCR in predicting antimicrobial resistance to four
antibiotic classes directly from Neisseria gonorrhoeae-positive extragenital specimens with
paired N. gonorrhoeae isolatesa
Reaction
Associated
antibiotic
No. of isolates with
the following result:
Sensitivity
(95% CI)b
Speciﬁcity
(95% CI)bTP FP FN TN Total
penA Asp345del  penA
Gly545Ser
ESCs 0 15c 0 39 54 NA 0.72 (0.58, 0.84)
23S rRNA C2611T and/or
23S rRNA A2059G
AZM 0 1 0 53 54 NA 0.98 (0.90, 1.00)
gyrA Ser91Phe CIP 23 1 0 30 54 1.00 (0.85, 1.00) 0.97 (0.83, 1.00)
16S rRNA C1192T SPC 0 2 0 52 54 NA 0.96 (0.87, 1.00)
aCI, conﬁdence interval; TP, true positive; FP, false positive; FN, false negative; TN, true negative; ESCs,
extended-spectrum cephalosporins; AZM, azithromycin; CIP, ciproﬂoxacin; SPC, spectinomycin; NA, not
applicable.
bSensitivity and speciﬁcity were calculated on the basis of the susceptibility phenotype (MICs) of the paired
culture isolates.
cTwo isolates were correctly predicted to harbor a mosaic penA allele on the basis of the molecular
characterization but were susceptible to ESCs.
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determinants should be included. Our results also show that the method does not
accurately predict AMR in extragenital samples.
We designed a SYBR green approach since it is inexpensive, it requires only speciﬁc
primers for the different reactions, and it is more feasible for application in low-income
settings; in addition, it is advantageous for translation into a point-of-care test. How-
ever, in light of our results, the implementation of molecular probes to increase the
speciﬁcity may represent a useful future optimization strategy.
Conclusions.We developed a rapid multitarget SYBR green-based method that was
successfully applied to accurately identify and predict the N. gonorrhoeae antimicrobial
resistance phenotype directly from urogenital samples in transport medium, which can
be also used to perform culture isolation concomitantly. However, our data showed
that the method cannot be used for some extragenital specimens, particularly pharyn-
geal samples, because of the lower gonococcal load, the higher risk of DNA degrada-
tion, and the cross-reactivity with other Neisseria spp. Nevertheless, owing to its ease of
use and rapidity, this method might be a promising candidate for further development
into a rapid test. Such a test, if deployed at the point of care, could contribute to
individually tailored gonorrhea treatments in the future.
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